According to the drug clinical trial registration and information publicity platform of the State Food and Drug Administration, AstraZeneca registered a phase IIIb study (CAPItrue) for advanced breast cancer in China on August 7, in which Capivacertib+Fluvison was used to treat HR+/HER2- disease progression after 1-2L endocrine therapy.